<DOC>
	<DOCNO>NCT02908529</DOCNO>
	<brief_summary>Obstructive sleep apnea ( OSA ) common major health implication treatment option limit . OSA patient show marked reduction upper airway ( UA ) dilator muscle activity sleep onset phenomenon lead increase collapsibility UA compare normal subject . Until recently , search medicine activate pharyngeal muscle sleep human discourage . However , excite new animal research show drug noradrenergic antimuscarinic effect restore pharyngeal muscle activity waking level . In protocol investigator test effect atomoxetine ( norepinephrine reuptake inhibitor ) oxybutynin ( antimuscarinic drug ) administer together OSA phenotype trait OSA severity sleep .</brief_summary>
	<brief_title>Atomoxetine Oxybutynin Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Inclusion Criterion : AHI &gt; 20 Any medical condition well control hypertension . Any medication know influence breathing , sleep/arousal muscle physiology . Claustrophobia . Inability sleep supine . Allergy lidocaine , Oxymetazoline HCl , atomoxetine/oxybutynin . Individuals underlie cardiac disease , arrhythmia . Individuals take psychiatric medication , atomoxetine , study medication medical care . History seizure For woman : Pregnancy . History panic disorder / hyperventilation syndrome / Attention deficithyperactivity disorder ( ADHD ) / autism</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>